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1. Introduction  
 
It is widely accepted that the unique painful and non-painful sensations in neuropathic pain 
are the result of particular mechanisms, and that specific management strategies for 
neuropathic pain should be applied to tackle them. Ideally, the treatment of chronic pain 
should be directed at eliminating the cause of pain, but in reality this is rarely possible. The 
management of chronic pain is therefore often limited to reducing the intensity of such pain 
and associated symptoms.  
 
Pain is essentially a subjective phenomenon described with patient-specific symptoms and 
expressed with a certain intensity. It therefore makes sense to examine the value of verbal 
descriptors and pain qualities as a basis for distinguishing neuropathic pain from other types 
of chronic pain. Work by Dubuisson and Melzack (1976) and later by Boureau et al. (1990) 
supported anecdotal opinion that key words might be discriminatory for neuropathic pain. In 
the last 5 years, much research has been undertaken to develop screening tools for this 
purpose. These tools are based on verbal pain description with, or without, limited bedside 
testing. This paper reviews the strengths and weaknesses of such tools.  
 
2. Current screening tools for neuropathic pain  
 
2.1. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)  
 
The LANSS was the first tool to be developed and contains 5 symptom items and 2 clinical 
examination items, and is easy to score within clinical settings (Bennett, 2001). It has recently 
been validated as a self-report tool, the S-LANSS (Bennett et al., 2005). The original LANSS 
was developed in a sample of 60 patients with chronic nociceptive or neuropathic pain and 
validated in a further sample of 40 patients. Sensitivity and specificity in the latter group were 
85% and 80%, respectively, compared to clinical diagnosis.  
 
The LANSS has subsequently been tested and validated in several settings (e.g. Potter et al., 
2003; Yucel et al., 2004; Kaki et al., 2005) with sensitivity and specificity ranging from 82% 
to 91% and 80% to 94% respectively, compared to clinical diagnosis. Although the LANSS 
was not designed as a measurement tool, it has also shown sensitivity to treatment effects 
(Khedr et al., 2005). Positive scores on the LANSS or S-LANSS identify patients with pain of 
predominantly neuropathic origin (POPNO) i.e., pain that is dominated by neuropathic 
mechanisms.  
 
2.2. Neuropathic Pain Questionnaire (NPQ)  
 
The NPQ consists of 12 items that include 10 related to sensations or sensory responses, and 2 
related to affect (Krause and Backonja, 2003). It was developed in 382 patients with a broad 
range of chronic pain diagnoses. The discriminant function was initially calculated on a 
random sample of 75% of the patients, and then cross-validated in the remaining 25%. The 
NPQ demonstrated 66% sensitivity and 74% specificity compared to clinical diagnosis in the 
validation sample. The short form of the NPQ maintained similar discriminative properties 
with only 3 items (numbness, tingling and pain increase in response to touch) (Backonja and 
Krause, 2003).  
 
2.3. Douleur Neuropathique en 4 questions (DN4)  
 
The DN4 was developed in 160 patients with either neuropathic or nociceptive pain and 
consists of 7 items related to symptoms and 3 related to clinical examination (Bouhassira et 
al., 2005). The DN4 is easy to score and a total score of 4 out of 10 or more suggests 
neuropathic pain. The DN4 showed 83% sensitivity and 90% specificity when compared to 
clinical diagnosis in the development study. The 7 sensory descriptors can be used as a self-
report questionnaire with similar results (Bouhassira et al., 2005). The tool was developed and 
validated in French and is being translated into other languages.  
 
2.4. painDETECT  
 
painDETECT was developed and validated in German (Freynhagen et al., 2005, 2006) and 
incorporates an easy to use patient-based (self-report) questionnaire with 9 items that do not 
require a clinical examination. There are 7 weighted sensory descriptor items (never to very 
strongly) and 2 items relating to the spatial (radiating) and temporal characteristics of the 
individual pain pattern. This questionnaire was validated in a multicentre study of 392 
patients with either neuropathic (n = 167) or nociceptive pain (n = 225), as well as a 
population of patients with low back pain. The tool correctly classified 83%of patients to their 
diagnostic group with a sensitivity of 85% and a specificity of 80%. It is also available in 
English.  
 
2.5. ID-Pain  
 
ID-Pain consists of 5 sensory descriptor items and 1 item relating to whether pain is located in 
the joints (used to identify nociceptive pain); it also does not require a clinical examination 
(Portenoy, 2006). The tool was developed in 586 patients with chronic pain of nociceptive, 
mixed or neuropathic etiology, and validated in 308 patients with similar pain classification. 
The tool was designed to screen for the likely presence of a neuropathic component to the 
patient’s pain. In the validation study, 22% of the nociceptive group, 39% of the mixed group, 
and 58% of the neuropathic group scored above 3 points, the recommended cut-off score.  
 
2.6. Screening tool content  
 
Despite the differences in development of these tools, all five make use of similar language to 
discriminate patients with neuropathic pain from those with other types of chronic pain with 
up to 80% sensitivity and specificity (see Table 1). This is powerful evidence for the 
reliability and validity of this approach, though further validation of these standardized tools 
is needed across cultures and languages. Their use by other clinicians and researchers is 
needed to reach consensus on which tool is most suited for a particular context or task.  
 
3. Limitations  
 
3.1. Independent validation  
 
The conceptual basis of these tools is that they standardize distinguishing features associated 
with neuropathic pain and attempt to reduce a comprehensive clinical evaluation to few key 
criteria in order to make this process more reproducible. The inevitable overlap with the gold 
standard clinical assessment introduces a bias that restricts the evaluation of a tool’s validity 
and is probably a limitation of their use. However, studies which used demonstrable nerve 
lesion as a gold standard ended with questionnaires with similar content to those that did not 
(Bennett et al., 2005; Bouhassira et al., 2005).  
 
3.2. Complex relationship between symptoms and pain mechanisms  
 
A complex relationship exists between disease etiology and pain mechanisms, such that any 
symptoms or signs that indicate the presence of neuropathic pain do not readily translate into 
particular pain mechanisms (Scholz and Woolf, 2002; Jensen and Baron, 2003; Backonja and 
Argoff, 2005; Baron, 2006). This is illustrated by a recent study that compared the results of 
detailed sensory testing and verbal pain description using the short form McGill Pain 
Questionnaire (Rasmussen et al., 2004a). The authors proposed clinical criteria for 
neuropathic pain-based on pain etiology and presence of sensory loss, and labeled patients as 
having ‘unlikely’, ‘possible’ and ‘definite’ neuropathic pain. The authors found no differences 
in verbal description across the groups, and demonstrated considerable variation in sensory 
abnormalities (e.g. 57% of the ‘unlikely’ neuropathic pain group had sensory abnormalities).  
 
4. Role of screening tools in clinical practice and research  
 
4.1. Bridging the gap between definition and diagnosis  
 
The International Association for the Study of Pain (IASP) defines neuropathic pain as ‘pain 
initiated or caused by a primary lesion or dysfunction in the nervous system’ (Merskey and 
Bogduk, 1994). This definition appears simple to use in clinical practice, but in fact it 
describes two broad categories of potential underlying pain mechanisms and not how to 
recognize them. Patients typically present with symptoms rather than easily recognizable 
neurological lesions. Clinicians then have to work through these verbal descriptions without a 
reference standard for what is a symptom of neuropathic pain because none were included in 
the IASP definition.  
 
In most cases of chronic pain, it is difficult to establish the presence or absence of nerve 
dysfunction, regardless of symptoms (Aggarwal et al., 2006). Many clinicians that manage 
patients with chronic pain, in both primary and secondary care, do not have adequate skill or 
time for a thorough neurological examination. Neither do they have easy access to 
quantitative sensory testing and so treatment decisions are supported by basic clinical 
evidence alone.  
 
Until consensus is agreed on a diagnostic approach to neuropathic pain, screening tools will 
serve to identify potential patients with neuropathic pain, particularly by non-specialists and 
this is probably their chief clinical strength. Their ease of use by professionals and patients 
alike, in clinic or via telephone or internet, makes these screening tools attractive because they 
provide immediately available information. Clinicians should then be alerted to undertake 
further assessment, which may subsequently influence management decisions. Screening tools 
fail to identify about 10–20% of patients with clinician diagnosed neuropathic pain indicating 
that they may offer guidance for further diagnostic evaluation and pain management but 
clearly, they do not replace clinical judgment.  
 
4.2. Standardizing identification of patients in research studies  
 
The lack of clinical criteria that result from the IASP definition is likely to result in significant 
variance between clinicians when recruiting patients to research studies and makes study 
populations difficult to compare. Commonly, authors of research studies either focus on 
single disease groups or present lists of etiologies to support their classification of neuropathic 
pain. Although this approach offers some face validity, it does not allow for standardized 
comparisons regarding the impact of any specific intervention on pain qualities.  
 
Screening tools can be used as standardized case identification tools in epidemiological 
studies, and this is probably their chief research strength. The lack of reliable epidemiological 
data has hampered progress in understanding the clinical impact of neuropathic pain and 
associated features. Studies using the S-LANSS (Torrance et al., 2006) and painDETECT 
(Freynhagen et al., 2006) indicate that standardized tools improve the quality of 
epidemiological data, and similar ongoing studies using DN4 will report soon. Standardized 
screening tools for neuropathic pain may also be useful in future trials of new therapies 
because they might help assess treatment efficacy for a specific symptom, or symptom 
combination, rather than to a disease entity (Jensen, 2005).  
 
4.3. Improving sensitivity in clinical measurement  
 
An important challenge facing clinical research is to reduce the gap between the rapid 
progress made by basic science, which has revealed a multitude of underlying mechanisms, 
and the slow progress in clinical practice, where standardizing measurement approaches has 
been difficult.  
 
Without specific neuropathic pain screening tools, it may be difficult to separate patients into 
categories of diagnostic certainty (Rasmussen et al., 2004a). One study compared responses to 
the S-LANSS and the Neuropathic Pain Scale (a measurement tool rather than a screening 
tool (Galer and Jensen, 1997) with clinician ratings of certainty in 200 chronic pain patients 
and illustrates the need for a standardized approach (Bennett et al., 2006). In this study, three 
groups of ‘unlikely’, ‘possible’ and ‘definite’ neuropathic pain were formed and significant 
differences in S-LANSS and Neuropathic Pain Scale scores were found between the groups. 
Using more sensitive tools for verbal description, a spectrum phenomenon was demonstrated 
for chronic pain, with various expressions of neuropathic features. The concept that chronic 
pain may be more or less neuropathic is novel, and relatively untested, but seems to have 
construct validity (Backonja, 2003; Attal and Bouhassira, 2004; Bennett et al., 2006) and fits 
well with basic science opinion regarding chronic pain mechanisms (Bennett, 2006).  
 
4.4. Screening tools in further research  
 
Despite the widespread acceptance of the need to identify patients with neuropathic pain, 
what evidence exists to support this approach? One study demonstrated that clinical 
examination did not predict the outcome of therapy with imipramine or gabapentin in patients 
with suspected neuropathic pain. (Rasmussen et al., 2004b). A critical analysis of previous 
clinical trials concluded that despite the logic of a mechanism-based approach to therapy, 
evidence supporting its success remains inconclusive (Finnerup and Jensen, 2006). An 
intriguing research question is therefore ‘do patients that score positively on these screening 
tools respond differentially to therapy from those that do not, regardless of exact pathological 
mechanism?’  
 
Meanwhile, it is likely that neuropathic pain screening tools will gain increasing acceptance 
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